Mathai Mammen, M.D., Ph.D. Chairman, CEO, & President, Parabilis Medicines Mathai Mammen, M.D., Ph.D., is Chairman, CEO, and President of Parabilis Medicines, a biopharmaceutical company pioneering therapies for previously undruggable protein targets in oncology. Previously, Mathai served as Global Head of R&D and a member of the Executive Committee at Johnson & Johnson. There, he led and evolved one of the world’s largest pharmaceutical R&D organizations and spearheaded the strategic integration of data science and AI across the portfolio. During his tenure, his team secured global approvals for nine medicines—including Tremfya™, Darzalex Faspro™, Carvykti™, Tecvayli™, and Spravato™—and achieved an unprecedented 90% success rate in Phase 2 to Phase 3 transitions. He also oversaw 40+ acquisitions and licenses, including the acquisition of Inlexzo™, along with 350+ strategic partnerships that expanded J&J’s portfolio and capabilities. Before J&J, Mathai was SVP at Merck, contributing to the development of Keytruda™ and the discovery of enlicitide, and earlier co-founded Theravance, Inc., where he led R&D toward five approved therapies including Breo™, Anoro™, and Trelegy™. In total, he has led the discovery/development of 18 approved medicines. Mathai’s leadership philosophy rejects incrementalism in favor of unique, high-efficacy science with meaningful global impact, regardless of difficulty. He builds cross-disciplinary teams that integrate scientific rigor and advanced analytics, including AI and strategic business insight, to accelerate transformational innovation. He serves on the boards of Sandoz, Xaira, Kelonia, and GBH, and is an advisor to General Atlantic and Foresite Capital. He holds an M.D. from Harvard/MIT (HST) and a Ph.D. from Harvard University.